Comparison of the diagnostic efficacy of 68  Ga-FAPI-04 PET/MR and 18 F-FDG PET/CT in patients with pancreatic cancer

• Published in: European journal of nuclear medicine and molecular imaging 2022-07, Vol.49 (8), p.2877
• Main Authors: Zhang, Zeyu, Jia, Guorong, Pan, Guixia, Cao, Kai, Yang, Qinqin, Meng, Hongyu, Yang, Jian, Zhang, Lu, Wang, Tao, Cheng, Chao, Zuo, Changjing
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Pancreatic Neoplasms; Pancreatic Neoplasms - diagnostic imaging; Positron Emission Tomography Computed Tomography - methods; Quinolines
• ISSN: 1619-7089
• DOI: 10.1007/s00259-022-05729-5

We sought to assess the performance of  Ga-FAPI-04 PET/MR for the diagnosis of primary tumours as well as metastatic lesions in patients with pancreatic cancer and to compare the results with those of F-FDG PET/CT. Prospectively, we evaluated 33 patients suspected to have pancreatic adenocarcinoma, of whom thirty-two were confirmed by histopathology, and one had autoimmune pancreatitis confirmed by needle biopsy and glucocorticoid treatment. Within 1 week, each patient underwent both  Ga-FAPI-04 PET/MR and F-FDG PET/CT. Comparisons of the detection abilities for primary tumours, lymph nodes, and metastases were conducted for the two imaging approaches. The original maximum standard uptake values (SUV ) and normalised SUV (SUV /SUV ) of paired lesions on  Ga-FAPI-04 PET/MR and F-FDG PET/CT were measured and compared. Thirty pancreatic cancer patients and three pancreatitis patients were enrolled.  Ga-FAPI-04 PET/MR and F-FDG PET/CT exhibited equivalent (100%) detection rates for primary tumours. The original/normalised SUV of primary tumours on  Ga-FAPI-04 PET was markedly higher than that on F-FDG (p